A Double-blind, Randomized, Placebo-controlled, Two-centre, Phase IIa Pharmacodynamic Cross-over Study to Assess the Effect of AZD2516 on the Total Number of Reflux Episodes in Healthy Male Volunteers.

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Two-centre, Phase IIa Pharmacodynamic Cross-over Study to Assess the Effect of AZD2516 on the Total Number of Reflux Episodes in Healthy Male Volunteers.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2012

At a glance

  • Drugs AZD 2516 (Primary)
  • Indications Gastro-oesophageal reflux; Neuropathic pain
  • Focus Pharmacodynamics
  • Most Recent Events

    • 05 Jul 2012 Actual patient number changed from 25 to 20 as reported by ClinicalTrials.gov.
    • 06 Dec 2010 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
    • 26 Nov 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top